CL2020000491A1 - Métodos para aumentar y/o estabilizar la función cardiaca en pacientes con enfermedad de fabry. - Google Patents
Métodos para aumentar y/o estabilizar la función cardiaca en pacientes con enfermedad de fabry.Info
- Publication number
- CL2020000491A1 CL2020000491A1 CL2020000491A CL2020000491A CL2020000491A1 CL 2020000491 A1 CL2020000491 A1 CL 2020000491A1 CL 2020000491 A CL2020000491 A CL 2020000491A CL 2020000491 A CL2020000491 A CL 2020000491A CL 2020000491 A1 CL2020000491 A1 CL 2020000491A1
- Authority
- CL
- Chile
- Prior art keywords
- patients
- increase
- methods
- cardiac function
- fabry disease
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 208000024720 Fabry Disease Diseases 0.000 title abstract 3
- 230000004217 heart function Effects 0.000 title abstract 2
- 239000012458 free base Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
SE PROVEEN MÉTODOS PARA EL TRATAMIENTO DE LA ENFERMEDAD DE FABRY EN UN PACIENTE. CIERTOS MÉTODOS SE RELACIONAN CON EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE FABRY QUE SE HAN SOMETIDO O QUE NO SE HAN SOMETIDO PREVIAMENTE A UNA ERT. CIERTOS MÉTODOS COMPRENDEN ADMINISTRAR AL PACIENTE ENTRE APROXIMADAMENTE 100 MG Y APROXIMADAMENTE 150 MG EQUIVALENTES DE BASE LIBRE DE MIGALASTAT PARA AUMENTAR Y/O ESTABILIZAR LA FUNCIÓN CARDIACA.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762550984P | 2017-08-28 | 2017-08-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2020000491A1 true CL2020000491A1 (es) | 2020-09-11 |
Family
ID=63528948
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2020000491A CL2020000491A1 (es) | 2017-08-28 | 2020-02-28 | Métodos para aumentar y/o estabilizar la función cardiaca en pacientes con enfermedad de fabry. |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20200222377A1 (es) |
| EP (2) | EP3675853B1 (es) |
| JP (2) | JP2020531550A (es) |
| KR (1) | KR20200044908A (es) |
| CN (1) | CN111770753A (es) |
| AR (1) | AR112482A1 (es) |
| AU (1) | AU2018326364A1 (es) |
| BR (1) | BR112020003974A2 (es) |
| CA (1) | CA3074450A1 (es) |
| CL (1) | CL2020000491A1 (es) |
| DK (1) | DK3675853T3 (es) |
| EA (1) | EA202090564A1 (es) |
| ES (1) | ES2931054T3 (es) |
| HR (1) | HRP20221366T1 (es) |
| HU (1) | HUE060287T2 (es) |
| IL (2) | IL310648A (es) |
| LT (1) | LT3675853T (es) |
| MX (2) | MX2020002229A (es) |
| PL (1) | PL3675853T3 (es) |
| PT (1) | PT3675853T (es) |
| RS (1) | RS63742B1 (es) |
| SG (1) | SG11202001707PA (es) |
| TW (1) | TW201919619A (es) |
| WO (1) | WO2019046244A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX351004B (es) | 2006-05-16 | 2017-09-26 | Nat Institutes Of Health | Ensayos para diagnosticar y evaluar opciones de tratamiento para enfermedad de fabry. |
| PT3470077T (pt) | 2008-02-12 | 2020-11-30 | Amicus Therapeutics Inc | Método para previsão da resposta ao tratamento farmacológico de doenças com chaperonas |
| AU2018277756A1 (en) | 2017-05-30 | 2020-01-23 | Amicus Therapeutics, Inc. | Methods of treating fabry patients having renal impairment |
| KR20200128676A (ko) | 2018-02-06 | 2020-11-16 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 임신 환자의 파브리병 치료를 위한 미갈라스타트의 용도 |
| EP3895708A3 (en) * | 2019-08-07 | 2022-01-19 | Amicus Therapeutics, Inc. | Methods of treating fabry disease in patients having a mutation in the gla gene |
| US11623916B2 (en) | 2020-12-16 | 2023-04-11 | Amicus Therapeutics, Inc. | Highly purified batches of pharmaceutical grade migalastat and methods of producing the same |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6274597B1 (en) | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
| CA2682441A1 (en) | 2007-03-30 | 2008-10-09 | Amicus Therapeutics, Inc. | Method for the treatment of fabry disease using pharmacological chaperones |
| US9999618B2 (en) * | 2007-04-26 | 2018-06-19 | Amicus Therapeutics, Inc. | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
| PT3470077T (pt) | 2008-02-12 | 2020-11-30 | Amicus Therapeutics Inc | Método para previsão da resposta ao tratamento farmacológico de doenças com chaperonas |
-
2018
- 2018-08-28 AU AU2018326364A patent/AU2018326364A1/en active Pending
- 2018-08-28 WO PCT/US2018/048257 patent/WO2019046244A1/en unknown
- 2018-08-28 LT LTEPPCT/US2018/048257T patent/LT3675853T/lt unknown
- 2018-08-28 SG SG11202001707PA patent/SG11202001707PA/en unknown
- 2018-08-28 IL IL310648A patent/IL310648A/en unknown
- 2018-08-28 HR HRP20221366TT patent/HRP20221366T1/hr unknown
- 2018-08-28 PT PT187664826T patent/PT3675853T/pt unknown
- 2018-08-28 DK DK18766482.6T patent/DK3675853T3/da active
- 2018-08-28 BR BR112020003974-8A patent/BR112020003974A2/pt unknown
- 2018-08-28 PL PL18766482.6T patent/PL3675853T3/pl unknown
- 2018-08-28 ES ES18766482T patent/ES2931054T3/es active Active
- 2018-08-28 EA EA202090564A patent/EA202090564A1/ru unknown
- 2018-08-28 HU HUE18766482A patent/HUE060287T2/hu unknown
- 2018-08-28 TW TW107129901A patent/TW201919619A/zh unknown
- 2018-08-28 CA CA3074450A patent/CA3074450A1/en active Pending
- 2018-08-28 MX MX2020002229A patent/MX2020002229A/es unknown
- 2018-08-28 IL IL272893A patent/IL272893B1/en unknown
- 2018-08-28 CN CN201880056413.8A patent/CN111770753A/zh active Pending
- 2018-08-28 AR ARP180102438 patent/AR112482A1/es unknown
- 2018-08-28 EP EP18766482.6A patent/EP3675853B1/en active Active
- 2018-08-28 EP EP22194251.9A patent/EP4176877A1/en active Pending
- 2018-08-28 RS RS20221061A patent/RS63742B1/sr unknown
- 2018-08-28 JP JP2020511971A patent/JP2020531550A/ja active Pending
- 2018-08-28 KR KR1020207008736A patent/KR20200044908A/ko not_active Application Discontinuation
- 2018-08-28 US US16/642,620 patent/US20200222377A1/en active Pending
-
2020
- 2020-02-27 MX MX2023005628A patent/MX2023005628A/es unknown
- 2020-02-28 CL CL2020000491A patent/CL2020000491A1/es unknown
-
2022
- 2022-12-20 JP JP2022203783A patent/JP2023051998A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| SG11202001707PA (en) | 2020-03-30 |
| HRP20221366T1 (hr) | 2023-01-06 |
| IL310648A (en) | 2024-04-01 |
| IL272893B1 (en) | 2024-03-01 |
| EP4176877A1 (en) | 2023-05-10 |
| JP2020531550A (ja) | 2020-11-05 |
| DK3675853T3 (da) | 2022-11-28 |
| CA3074450A1 (en) | 2019-03-07 |
| BR112020003974A2 (pt) | 2020-09-01 |
| CN111770753A (zh) | 2020-10-13 |
| EP3675853B1 (en) | 2022-09-07 |
| WO2019046244A1 (en) | 2019-03-07 |
| RS63742B1 (sr) | 2022-12-30 |
| AR112482A1 (es) | 2019-10-30 |
| TW201919619A (zh) | 2019-06-01 |
| US20200222377A1 (en) | 2020-07-16 |
| KR20200044908A (ko) | 2020-04-29 |
| HUE060287T2 (hu) | 2023-02-28 |
| MX2023005628A (es) | 2023-05-24 |
| PT3675853T (pt) | 2022-11-28 |
| JP2023051998A (ja) | 2023-04-11 |
| ES2931054T3 (es) | 2022-12-23 |
| AU2018326364A1 (en) | 2020-04-09 |
| EA202090564A1 (ru) | 2020-06-15 |
| PL3675853T3 (pl) | 2022-12-27 |
| IL272893A (en) | 2020-04-30 |
| LT3675853T (lt) | 2022-12-12 |
| MX2020002229A (es) | 2020-07-20 |
| EP3675853A1 (en) | 2020-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020000491A1 (es) | Métodos para aumentar y/o estabilizar la función cardiaca en pacientes con enfermedad de fabry. | |
| CL2018001677A1 (es) | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert | |
| CY1124135T1 (el) | Δοσολογικα σχηματα για την αγωγη της νοσου ρομρε | |
| CL2019003496A1 (es) | Métodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal. | |
| JOP20200156A1 (ar) | إيسكيتامين لعلاج الاكتئاب | |
| AR089862A1 (es) | USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA | |
| AR049985A1 (es) | Tratamiento de combinacion para enfermedades malignas no hematologicas | |
| AR111374A1 (es) | Uso de lik066 en pacientes con insuficiencia cardíaca | |
| MX2021002321A (es) | Nuevos metodos. | |
| EA202090242A1 (ru) | Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов | |
| BR112013010829B8 (pt) | Composição farmacêutica intravenosa para proporcionar alívio da dor e/ou da inflamação | |
| CL2022000786A1 (es) | Metodos de tratamiento para modificar la hemodinamica | |
| NI201700024A (es) | Tratamientos médicos a base de anamorelina | |
| PH12015502655A1 (en) | Method | |
| UY31790A (es) | Utilización de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administración de dronedarona | |
| EA202191165A1 (ru) | Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы | |
| BR112018007399A2 (pt) | composição, método de tratamento, kit de partes e forma de dosagem | |
| CO2022004947A2 (es) | Regímenes de dosificación para el tratamiento de pacientes con carcinoma de células escamosas avanzado localmente | |
| UY31499A1 (es) | Nuevo uso medico de las sales de propionato 3- (2,2,2-trimetilhydrazinio) en el trtamiento de la enfermedad cardiaca isquemica | |
| AR111971A1 (es) | Métodos para tratar pacientes con enfermedad de fabry que tienen insuficiencia renal | |
| MX2020007627A (es) | Uso de la carrimicina o de sus ingredientes activos. | |
| MX2021007324A (es) | Terapia oral con acido 6,8-bis-benciltio-octanoico. | |
| AR109102A1 (es) | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert | |
| Fawcett | Nausea and irritability: 4 case reports | |
| EA202190247A1 (ru) | ПРИМЕНЕНИЕ рГЦ СТИМУЛЯТОРОВ ДЛЯ ЛЕЧЕНИЯ МИТОХОНДРИАЛЬНЫХ ЗАБОЛЕВАНИЙ |